216 related articles for article (PubMed ID: 15114252)
1. NovoSeven for non-hemophilia hemostasis.
Med Lett Drugs Ther; 2004 Apr; 46(1181):33-4. PubMed ID: 15114252
[No Abstract] [Full Text] [Related]
2. rFVIIa (Novoseven): the new panacea?
Ickx BE
Acta Anaesthesiol Belg; 2003; 54(4):333-5. PubMed ID: 14719355
[No Abstract] [Full Text] [Related]
3. The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication?
Negrier C
J Thromb Haemost; 2003 Mar; 1(3):423-4. PubMed ID: 12871444
[No Abstract] [Full Text] [Related]
4. [Administration of activated recombinant factor VII (novo seven) for the control of massive bleeding in gynecology].
Tanchev S; Pandurski F; Georgiev A; Gesheva Iu; Platikanov V; Dinov P
Akush Ginekol (Sofiia); 2004; 43 Suppl 2():32-5. PubMed ID: 15518274
[TBL] [Abstract][Full Text] [Related]
5. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.
Mohr AM; Holcomb JB; Dutton RP; Duranteau J
Crit Care; 2005; 9 Suppl 5(Suppl 5):S37-42. PubMed ID: 16221318
[TBL] [Abstract][Full Text] [Related]
6. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
Weiskopf RB
Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
[TBL] [Abstract][Full Text] [Related]
7. A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.
Chuansumrit A; Sri-Udomporn N; Srimuninnimit V; Juntarukha R
Haemophilia; 2001 Sep; 7(5):532-4. PubMed ID: 11554948
[No Abstract] [Full Text] [Related]
8. Recombinant factor VIIa (NovoSeven) as a hemostatic agent.
Hedner U
Dis Mon; 2003 Jan; 49(1):39-48. PubMed ID: 12525827
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic decision-making in inhibitor patients.
Allen G; Aledort L
Am J Hematol; 2006 Jan; 81(1):71-2. PubMed ID: 16369965
[TBL] [Abstract][Full Text] [Related]
10. [Place of recombinant activated factor VII in the treatment of severe haemorrhage in paediatric patients].
Veyckemans F
Ann Fr Anesth Reanim; 2009; 28(7-8):676-7. PubMed ID: 19574019
[No Abstract] [Full Text] [Related]
11. Recombinant factor VIIa: a general hemostatic agent? Yes.
Roberts HR
J Thromb Haemost; 2004 Oct; 2(10):1691-4. PubMed ID: 15456475
[No Abstract] [Full Text] [Related]
12. Recombinant FVIIa in the treatment of bleeding in acquired hemophilia.
Guerin V; Chossat I; Dutronc H; Dubreuil M; Valentin F
Am J Hematol; 2002 Aug; 70(4):333. PubMed ID: 12210820
[No Abstract] [Full Text] [Related]
13. Recombinant factor VIIa: a general hemostatic agent? Not yet.
Levi M
J Thromb Haemost; 2004 Oct; 2(10):1695-7. PubMed ID: 15456476
[No Abstract] [Full Text] [Related]
14. Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer.
Franchini M; Capra F; Capelli C; de Maria E; Lippi G; Gandini G
Haematologica; 2001 Apr; 86(4):E12. PubMed ID: 11325664
[No Abstract] [Full Text] [Related]
15. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.
Stephens JM; Joshi AV; Sumner M; Botteman MF
Expert Opin Pharmacother; 2007 Jun; 8(8):1127-36. PubMed ID: 17516876
[TBL] [Abstract][Full Text] [Related]
16. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors.
Hedner U
J Thromb Haemost; 2006 Nov; 4(11):2498-500. PubMed ID: 16907841
[No Abstract] [Full Text] [Related]
17. Recombinant FVIIa.
Hedner U
Vox Sang; 2004 Jul; 87 Suppl 2():25-8. PubMed ID: 15209873
[No Abstract] [Full Text] [Related]
18. Recombinant factor VIIa: its background, development and clinical use.
Hedner U
Curr Opin Hematol; 2007 May; 14(3):225-9. PubMed ID: 17414211
[TBL] [Abstract][Full Text] [Related]
19. Thromboelastography and recombinant factor VIIa-hemophilia and beyond.
Sørensen B; Ingerslev J
Semin Hematol; 2004 Jan; 41(1 Suppl 1):140-4. PubMed ID: 14872435
[TBL] [Abstract][Full Text] [Related]
20. Effective treatment with recombinant factor VIIa of severe bleeding due to acquired factor VIII inhibitor and acquired thrombocytopathy.
Conesa V; Mompel A; Lopez F; Marín F; Ruiz J; Navarro F; Gomez A
Am J Hematol; 2002 Aug; 70(4):329-30. PubMed ID: 12210816
[No Abstract] [Full Text] [Related]
[Next] [New Search]
